Source comparison
Melanotan-1 Degradation Reconstituted: Research vs Compounded Comparison
Research-grade lyophilized (e.g., Real Peptides) ≥98% 90–95% potency retention with proper storage CoA with HPLC, mass spec verification per batch In vitro studies, receptor binding assays, mechanism research Highest purity and batch consistency—necessary when
This comparison does not assign a generated winner or score.
- Research-grade lyophilized (e.g., Real Peptides)
- ≥98%
- 90–95% potency retention with proper storage
- CoA with HPLC, mass spec verification per batch
- In vitro studies, receptor binding assays, mechanism research
- Highest purity and batch consistency—necessary when reproducibility is critical
- Compounded for clinical use
- 95–98%
- 85–90% potency retention; variable by compounder
- CoA availability varies; often limited to potency testing
- Patient-facing applications under prescriber supervision
- Acceptable for clinical dosing but lacks analytical rigor for research conclusions
- Generic or unverified sources
- 85–95% (unverified claims common)
- 70–85% potency retention; higher aggregation risk
- Minimal or no third-party verification
- Not recommended for published research
- Potency and purity cannot be verified—introduces uncontrolled variables into study design
- The difference between research-grade and compounded Melanotan-1 isn't just initial purity—it's post-reconstitution predictability. Research-grade peptides from Real Peptides are synthesized in small batches with exact amino-acid sequencing and undergo HPLC verification to confirm ≥98% purity before release. This level of precision ensures that degradation rates post-reconstitution follow predictable kinetics, which is essential when interpreting dose-response curves or comparing results across study cohorts. Compounded peptides may contain the same active molecule but lack batch-to-batch consistency documentation, making it difficult to attribute observed variability to biological phenomena versus peptide quality drift.